Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Finished

MucOncoBots Drug-loaded nanobots for transmucosal delivery to mucinous tumours

Coordinator
Fundacio Institut De Bioenginyeria De Catalunya, Spain
Runs
1 October 2023 to 31 March 2025
Status
Finished
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101138723

What the project is doing

In the project's own words, from its summary on CORDIS.

Mucus is a defensive barrier that protects the underlying cells from pathogens and toxic compounds, although it also hinders the delivery of drugs whenever they are administered locally. There are different types of mucus-secreting tumours, such as pseudomyxoma peritonei (PMP), that could benefit from more efficient transmucosal delivery of anti-cancer drugs. PMP is a rare disease and the most mucinous tumour type, thus it will be used as a proof of concept for this project.

In fact, it is characterised by the production of abundant mucus in the peritoneal cavity and is treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, usually Mitomycin C. This approach has extended patient survival, but there is a significant proportion of recurrence, most probably due to the shielding effect of mucus. Therefore, there is an urgent need to offer new therapeutic strategies to PMP patients.

Recently, Dr. Palmer’s lab has established a collection of PMP patient-derived organoids and xenografts and has shown that some PMP patients present oncogenic BRAFV600E mutations, introducing a new druggable targeted mutation. In this proposal, Dr. Sánchez’s lab (IBEC), in collaboration with Dr. Palmer’s research group (VHIO), aims to use nanobots able to overcome the mucus barrier that will be loaded with Mitomycin C or Encorafenib (BRAF inhibitor) to treat PMP.

A comparative study will be performed to assess the treatment’s efficacy compared to the standard of care, and medical advice will be received from Dr. Élez (VHUH) to ensure the translation of the results to the clinic. We believe that using this all-in-one system will certainly enhance the delivery and efficacy of the active therapeutic compound, thus potentially improving current treatments.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainCoordinator
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI